It binds to HER2 on the cell surface and has been proven to be an effective treatment for HER2/neu-positive breast cancers in multiple animal studies and clinical trials (Abramson and Arteaga 2011; Hudis 2007; Moasser 2007). Here, ERBB2 is linked to breast cancer.